Serving the Society Since 1986
Advanced Search
Volume 41 Issue 5
October 2026
    Citation: Shuai Sui, Kaiyue Zhang, Xiaofan Shen, Xia Chuai, Sandra Chiu. Liver injury during Ebola virus infections: Characteristics and molecular mechanisms .VIROLOGICA SINICA, 2026, 41(5) : 1023-1032.  http://dx.doi.org/10.1016/j.virs.2026.08.015
    shu

    Liver injury during Ebola virus infections: Characteristics and molecular mechanisms

    • a. State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan 430207, China;

    • b. University of Chinese Academy of Sciences, Beijing 100049, China;

    • c. Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang 050017, China;

    • d. Department of Infectious Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China;

    • e. Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China;

    • f. Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei 230026, China

    • Corresponding author: Xia Chuai, qiux@ustc.edu.cn
      Sandra Chiu, chuaixia@wh.iov.cn
    • Received Date: 13 June 2026
      Accepted Date: 26 August 2026
      Available online: 28 August 2026
    • Ebola virus (EBOV) causes severe and often fatal Ebola virus disease (EVD) in humans, posing a major threat to global public health. Since EVD was first identified in the Democratic Republic of Congo (DRC) in 1976, the World Health Organization (WHO) has declared it a Public Health Emergency of International Concern (PHEIC) on three occasions. EBOV infection is characterized by rapid progression from non-specific febrile illness to severe gastrointestinal symptoms, followed by hemorrhagic fever and multi-organ dysfunction, with case fatality rates reaching as high as 90%. The liver is a primary target of EBOV, and virus-induced liver injury is characterized by elevated aspartate aminotransferase (AST) levels, mild hyperbilirubinemia, impaired coagulation factor synthesis, hepatocyte necrosis, and robust inflammatory responses, all of which are closely correlated with disease severity and mortality risk. In this review, we summarize the characteristics and mechanisms of EBOV-induced liver injury, which may help to further elucidate the pathogenesis of EVD and provide novel strategies for combating EBOV infection.
    • 加载中

      1. Barry M, Toure A, Traore FA, Sako FB, Sylla D, Kpamy DO, Bah EI, Bangoura M, Poncin M, Keita S, Tounkara TM, Cisse M, Vanhems P (2015) Clinical predictors of mortality in patients with Ebola virus disease. Clin Infect Dis 60:1821-1824.

      2. Beeching NJ, Fenech M, Houlihan CF (2014) Ebola virus disease. BMJ 349:g7348.

      3. Bodmer BS, Breithaupt A, Heung M, Brunetti JE, Henkel C, Muller-Guhl J, Rodriguez E, Wendt L, Winter SL, Vallbracht M, Muller A, Romer S, Chlanda P, Munoz-Fontela C, Hoenen T, Escudero-Perez B (2023) In vivo characterization of the novel ebolavirus Bombali virus suggests a low pathogenic potential for humans. Emerg Microbes Infect 12:2164216.

      4. Bodmer BS, Hoenen T (2022) Assessment of Life Cycle Modeling Systems as Prediction Tools for a Possible Attenuation of Recombinant Ebola Viruses. Viruses 14:1044.

      5. Bodmer BS, Hoenen T, Wendt L (2024) Molecular insights into the Ebola virus life cycle. Nat Microbiol 9:1417-1426.

      6. Bray M, Paragas J (2002) Experimental therapy of filovirus infections. Antiviral Res 54:1-17.

      7. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwiki KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, Van den Enden E, Van den Enden E (1999) Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179 Suppl 1:S1-7.

      8. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L (2020) COVID-19: Abnormal liver function tests. J Hepatol 73:566-574.

      9. Cao Z, Liu C, Peng C, Ran Y, Yao Y, Xiao G, Li E, Chen Z, Chuai X, Chiu S (2023) Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication. Virologica Sinica 38:922-930.

      10. Chavez S, Koyfman A, Gottlieb M, Brady WJ, Carius BM, Liang SY, Long B (2023) Ebola virus disease: A review for the emergency medicine clinician. Am J Emerg Med 70:30-40.

      11. Chen G, Hu X, Huang Y, Xiang X, Pan S, Chen R, Xu X (2023) Role of the immune system in liver transplantation and its implications for therapeutic interventions. MedComm (2020) 4:e444.

      12. Chen P, Yao L, Yuan M, Wang Z, Zhang Q, Jiang Y, Li L (2024) Mitochondrial dysfunction: A promising therapeutic target for liver diseases. Genes Dis 11:101115.

      13. Cheng Y, Zheng X (2025) Characteristics and mechanisms of liver injury caused by emerging infectious diseases. Front Immunol 16:1647517.

      14. de La Vega MA, Xiii A, Massey S, Spengler JR, Kobinger GP, Woolsey C (2024) An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses. Expert Opin Drug Discov 19:1185-1211.

      15. de Wit E, Rosenke K, Fischer RJ, Marzi A, Prescott J, Bushmaker T, van Doremalen N, Emery SL, Falzarano D, Feldmann F, Groseth A, Hoenen T, Juma B, McNally KL, Ochieng M, Omballa V, Onyango CO, Owuor C, Rowe T, Safronetz D, Self J, Williamson BN, Zemtsova G, Grolla A, Kobinger G, Rayfield M, Stroher U, Strong JE, Best SM, Ebihara H, Zoon KC, Nichol ST, Nyenswah TG, Bolay FK, Massaquoi M, Feldmann H, Fields B (2016) Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015. J Infect Dis 214:S169-S176.

      16. Durante D, Murugesh V, Kalanquin T, Gaisina IN, Rong L, Moore TW (2025) Small molecule drug discovery for Ebola virus disease. RSC Med Chem 16:4571-4598.

      17. Echavarria-Consuegra L, Cook GM, Busnadiego I, Lefevre C, Keep S, Brown K, Doyle N, Dowgier G, Franaszek K, Moore NA, Siddell SG, Bickerton E, Hale BG, Firth AE, Brierley I, Irigoyen N (2021) Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infection. PLoS Pathog 17:e1009644.

      18. Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377:849-862.

      19. Fowler RA, Fletcher T, Fischer WA, 2nd, Lamontagne F, Jacob S, Brett-Major D, Lawler JV, Jacquerioz FA, Houlihan C, O'Dempsey T, Ferri M, Adachi T, Lamah MC, Bah EI, Mayet T, Schieffelin J, McLellan SL, Senga M, Kato Y, Clement C, Mardel S, Vallenas Bejar De Villar RC, Shindo N, Bausch D (2014) Caring for critically ill patients with ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 190:733-737.

      20. Furuyama W, Marzi A (2019) Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol 6:435-458.

      21. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB (2000) Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80:171-186.

      22. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347-2370.

      23. Group PIS, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, Johnson KL, Gayedyu-Dennis D, Hensley LE, Higgs ES, Nath A, Tuznik K, Varughese J, Jensen KS, Dighero-Kemp B, Neaton JD, Lane HC, Fallah MP (2019) A Longitudinal Study of Ebola Sequelae in Liberia. N Engl J Med 380:924-934.

      24. Guzman-Lepe J, Cervantes-Alvarez E, Collin de l'Hortet A, Wang Y, Mars WM, Oda Y, Bekki Y, Shimokawa M, Wang H, Yoshizumi T, Maehara Y, Bell A, Fox IJ, Takeishi K, Soto-Gutierrez A (2018) Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. Hepatol Commun 2:582-594.

      25. Halstead SB (2025) Dengue, Dengue Hemorrhagic Fever, and Severe Dengue 10.1016/b978-0-323-82763-8.00184-9. Elsevier.

      26. Huang H, Shi W, Yan H, Fan L, Lu J, Long Z, Li X, Li J, Wang J, Liu L, Qian J (2025) Dual roles of CXCR4 (C-X-C motif chemokine receptor 4) in promoting entry of ebolavirus and targeting excessive glycoprotein for reticulophagic degradation to facilitate viral fitness. Autophagy 21:2148-2167.

      27. Jacob ST, Crozier I, Fischer WA, 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH (2020) Ebola virus disease. Nat Rev Dis Primers 6:13.

      28. Jankeel A, Menicucci AR, Woolsey C, Fenton KA, Mendoza N, Versteeg K, Cross RW, Geisbert TW, Messaoudi I (2020) Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques. J Virol 94:e00250-00220.

      29. Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T, Wu J, Tang H, Zheng S, Liu Y, Wu Y, Luo X, Xie Y, Ren J (2025) Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res 53:D1670-D1676.

      30. Kortepeter MG, Bausch DG, Bray M (2011) Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 204 Suppl 3:S810-816.

      31. Kuehn R, Ryan H, Okwaraeke KC, Gould S, Chaplin M, Riley M, Turtle L, Jacob ST, Fletcher T (2024) Vaccines for preventing Ebola virus disease. Cochrane Database Syst Rev 11:CD015828.

      32. Kumar MP, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, Mandavdhare HS, Dutta U, Sharma V (2020) Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int 14:711-722.

      33. Kupferschmidt K (2026) Scientists play catch-up to startling Ebola outbreak. Science 392:792-793.

      34. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Capobianchi MR, Strada G, Zumla A, Di Caro A, Ippolito G, Group I-EESLS (2018) Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. Clin Infect Dis 66:36-44.

      35. Leligdowicz A, Fischer WA, 2nd, Uyeki TM, Fletcher TE, Adhikari NK, Portella G, Lamontagne F, Clement C, Jacob ST, Rubinson L, Vanderschuren A, Hajek J, Murthy S, Ferri M, Crozier I, Ibrahima E, Lamah MC, Schieffelin JS, Brett-Major D, Bausch DG, Shindo N, Chan AK, O'Dempsey T, Mishra S, Jacobs M, Dickson S, Lyon GM, 3rd, Fowler RA (2016) Ebola virus disease and critical illness. Crit Care 20:217.

      36. Letafati A, Salahi Ardekani O, Karami H, Soleimani M (2023) Ebola virus disease: A narrative review. Microb Pathog 181:106213.

      37. Lindquist ME, Zeng X, Altamura LA, Daye SP, Delp KL, Blancett C, Coffin KM, Koehler JW, Coyne S, Shoemaker CJ, Garrison AR, Golden JW (2018) Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice. J Virol 92.

      38. Liu C, Cao Z, Peng C, Li F, Chen Z, Zhang X, Jia X, Zhou J, Mao W, Li E, Xiao G, Chiu S (2025) Integrative analysis of the metabolomes and transcriptomes of Ebola virus-infected cells: Uncovering pathways related to hepatic apoptosis. Genes Dis 12:101377.

      39. Liu CH, Hu YT, Wong SH, Lin LT (2022) Therapeutic Strategies against Ebola Virus Infection. Viruses 14:579.

      40. Liu K, Li Z, Li L, Heyward S, Wang SR, He L, Wang H (2024a) Mechanistic Understanding of Dexamethasone-Mediated Protection against Remdesivir-Induced Hepatotoxicity. Mol Pharmacol 106:71-82.

      41. Liu Q, He B, Huang SY, Wei F, Zhu XQ (2014) Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis 14:763-772.

      42. Liu X, Speranza E, Munoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng EG, Ludtke A, Xia D, Kerber R, Krumkamp R, Duraffour S, Sissoko D, Kenny J, Rockliffe N, Williamson ED, Laws TR, N'Faly M, Matthews DA, Gunther S, Cossins AR, Sprecher A, Connor JH, Carroll MW, Hiscox JA (2017) Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol 18:4.

      43. Liu Y, Xu C, Gu R, Han R, Li Z, Xu X (2024) Endoplasmic reticulum stress in diseases. MedComm (2020) 5:e701.

      44. Marcinkiewicz J, Bryniarski K, Nazimek K (2014) Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention. Folia Med Cracov 54:39-48.

      45. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR (2015) Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 235:153-174.

      46. Matson MJ, Chertow DS, Munster VJ (2025) Ebola Virus Disease: Uniquely Challenging Among the Viral Hemorrhagic Fevers. Open Forum Infect Dis 12:ofaf464.

      47. Nicholas VV, Rosenke R, Feldmann F, Long D, Thomas T, Scott DP, Feldmann H, Marzi A (2018) Distinct Biological Phenotypes of Marburg and Ravn Virus Infection in Macaques. J Infect Dis 218:S458-S465.

      48. Pan Z, Feng Y, Wang Z, Lei Z, Han Q, Zhang J (2022) MERS-CoV nsp1 impairs the cellular metabolic processes by selectively downregulating mRNAs in a novel granules. Virulence 13:355-369.

      49. Park SJ, Nkuba-Ndaye A, Muhindo-Wema K, Mulopo-Mukanya N, Kavira-Muhindo MA, Kwizera-Sendegeya J, Muloki-Nsele M, Morisho-Mungeleza M, Morisho-Mwanabiningo N, Mukadi-Bamuleka D (2026) Investigating the spatiotemporal links between the EVD outbreaks in Likati (2017) and Eastern DRC (2018-2020): a retrospective transdisciplinary study. BMC Infect Dis 26.

      50. Penas JA, Miranda ME, de Los Reyes VC, Sucaldito MNL, Magpantay RL (2019) Risk assessment of Ebola Reston virus in humans in the Philippines. Western Pac Surveill Response J 10:1-8.

      51. Phelan AL, Nuzzo JB, Gostin LO (2026) The PHEIC for Ebola disease caused by Bundibugyo virus: an inflection point for solidarity and health equity. Lancet 407:2264-2267.

      52. Prescott JB, Liu KJ, Lander A, Pek NMQ, Jha SK, Bokelmann M, Begur M, Koh PW, Yang H, Lim B, Red-Horse K, Weissman IL, Loh KM, Ang LT (2025) Metabolically purified human stem cell-derived hepatocytes reveal distinct effects of Ebola and Lassa viruses 10.1101/2025.02.17.638665. openRxiv.

      53. Qin E, Bi J, Zhao M, Wang Y, Guo T, Yan T, Li Z, Sun J, Zhang J, Chen S, Wu Y, Li J, Zhong Y (2015) Clinical Features of Patients With Ebola Virus Disease in Sierra Leone. Clin Infect Dis 61:491-495.

      54. Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley L, Bore JA, Koundouno R, Dudas G, Mikhail A, Ouedraogo N, Afrough B, Bah A, Baum JH, Becker-Ziaja B, Boettcher JP, Cabeza-Cabrerizo M, Camino-Sanchez A, Carter LL, Doerrbecker J, Enkirch T, Dorival IGG, Hetzelt N, Hinzmann J, Holm T, Kafetzopoulou LE, Koropogui M, Kosgey A, Kuisma E, Logue CH, Mazzarelli A, Meisel S, Mertens M, Michel J, Ngabo D, Nitzsche K, Pallash E, Patrono LV, Portmann J, Repits JG, Rickett NY, Sachse A, Singethan K, Vitoriano I, Yemanaberhan RL, Zekeng EG, Trina R, Bello A, Sall AA, Faye O, Faye O, Magassouba N, Williams CV, Amburgey V, Winona L, Davis E, Gerlach J, Washington F, Monteil V, Jourdain M, Bererd M, Camara A, Somlare H, Camara A, Gerard M, Bado G, Baillet B, Delaune D, Nebie KY, Diarra A, Savane Y, Pallawo RB, Gutierrez GJ, Milhano N, Roger I, Williams CJ, Yattara F, Lewandowski K, Taylor J, Rachwal P, Turner D, Pollakis G, Hiscox JA, Matthews DA, O'Shea MK, Johnston AM, Wilson D, Hutley E, Smit E, Di Caro A, Woelfel R, Stoecker K, Fleischmann E, Gabriel M, Weller SA, Koivogui L, Diallo B, Keita S, Rambaut A, Formenty P, Gunther S, Carroll MW (2016) Real-time, portable genome sequencing for Ebola surveillance. Nature 530:228-232.

      55. Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F (2020) The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol 7:HEP17.

      56. Rodrigues R, Paranhos-Baccala G, Vernet G, Peyrefitte CN (2012) Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk. PLoS One 7:e29712.

      57. Rodriguez-Espada A, Salgado-de la Mora M, Rodriguez-Paniagua BM, Limon-de la Rosa N, Martinez-Gutierrez MI, Pastrana-Brandes S, Navarro-Alvarez N (2024) Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications. World J Gastroenterol 30:2866-2880.

      58. Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Ansari AA, Gershwin ME, Anaya JM (2020) Ebola virus disease: An emerging and re-emerging viral threat. J Autoimmun 106:102375.

      59. Rollin PE, Bausch DG, Sanchez A (2007) Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 196 Suppl 2:S364-371.

      60. Schafer A, Marzi A, Furuyama W, Catanzaro NJ, Nguyen C, Haddock E, Feldmann F, Meade-White K, Thomas T, Hubbard ML, Gully KL, Leist SR, Hock P, Bell TA, De la Cruz GE, Midkiff BR, Martinez DR, Shaw GD, Miller DR, Vernon MJ, Graham RL, Cowley DO, Montgomery SA, Schughart K, de Villena FPM, Wilkerson GK, Ferris MT, Feldmann H, Baric RS (2024) Mapping of susceptibility loci for Ebola virus pathogenesis in mice. Cell Rep 43:114127.

      61. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371:2092-2100.

      62. Scoon WA, Mancio-Silva L, Suder EL, Villacorta-Martin C, Lindstrom-Vautrin J, Bernbaum JG, Mazur S, Johnson RF, Olejnik J, Flores EY, Mithal A, Wang F, Hume AJ, Kaserman JE, March-Riera S, Wilson AA, Bhatia SN, Muhlberger E, Mostoslavsky G (2022) Ebola virus infection induces a delayed type I IFN response in bystander cells and the shutdown of key liver genes in human iPSC-derived hepatocytes. Stem Cell Reports 17:2286-2302.

      63. Smither SJ, O'Brien LM, Eastaugh L, Woolley T, Lever S, Fletcher T, Parmar K, Hunt BJ, Watts S, Kirkman E (2019) Haemostatic Changes in Five Patients Infected with Ebola Virus. Viruses 11:647.

      64. Springer E, Schneider A, Trapani J, Hartmann D, Hueser N, Laschinger M, Knolle PA, Wohlleber D (2023) Hepatitis B virus infected hepatocytes are resistant to cell death induction by virus-specific T cells. Journal of Hepatology 78:S1021.

      65. Tomori O, Kolawole MO (2021) Ebola virus disease: current vaccine solutions. Curr Opin Immunol 71:27-33.

      66. Uyeki TM, Mehta AK, Davey RT, Jr., Liddell AM, Wolf T, Vetter P, Schmiedel S, Grunewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J, Working Group of the USECNoCMoEVDPitUS, Europe (2016) Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med 374:636-646.

      67. Velasquez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB (2015) Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review. Clin Infect Dis 61:1135-1140.

      68. Vernet MA, Reynard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Rives M, Georges N, Garcia-Bonnet N, Sylla AI, Grovogui P, Kerherve JY, Savio C, Savio-Coste S, de Severac ML, Zloczewski P, Linares S, Harouna S, Abdoul BM, Petitjean F, Samake N, Shepherd S, Kinda M, Koundouno FR, Joxe L, Mateo M, Lecine P, Page A, Tchamdja TM, Schoenhals M, Barbe S, Simon B, Tran-Minh T, Longuet C, L'Heriteau F, Baize S (2017) Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight 2:e88864.

      69. Vucetic A, Lafleur A, Cote M, Kobasa D, Chan M, Alvarez F, Piccirillo C, Dong G, Olivier M (2023) Extracellular vesicle storm during the course of Ebola virus infection in primates. Front Cell Infect Microbiol 13:1275277.

      70. Wang B, Wang Y, Frabutt DA, Zhang X, Yao X, Hu D, Zhang Z, Liu C, Zheng S, Xiang SH, Zheng YH (2017) Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. J Biol Chem 292:5860-5870.

      71. Wanninger TG, Saldarriaga OA, Arroyave E, Millian DE, Comer JE, Paessler S, Stevenson HL (2024) Hepatic and pulmonary macrophage activity in a mucosal challenge model of Ebola virus disease. Front Immunol 15:1439971.

      72. Xu Z, Jin B, Teng G, Rong Y, Sun L, Zhang J, Du N, Liu L, Su H, Yuan Y, Chen H (2016) Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone. Am J Infect Control 44:1285-1290.

      73. Yang W, Li W, Zhou W, Wang S, Wang W, Wang Z, Feng N, Wang T, Xie Y, Zhao Y, Yan F, Xia X (2024) Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory. Virologica Sinica 39:434-446.

      74. Zaki SR, Goldsmith CS (1999) Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 235:97-116.

      75. Zhang X, Liao Y, Liu X, Zhou J, Gao P, Dong X, Pan S, Duan H, Liu J, Chi X, Yang W (2026) Nanobody targeting glycan cap confers broad orthoebolavirus neutralization. Virologica Sinica 41:413-422.

    • 加载中

    Figures(1)

    PDF

    Article Metrics

    Article views(12) PDF downloads(0) Cited by()

    Related
    Proportional views

      Liver injury during Ebola virus infections: Characteristics and molecular mechanisms

        Corresponding author: Xia Chuai, qiux@ustc.edu.cn
        Corresponding author: Sandra Chiu, chuaixia@wh.iov.cn
      • a. State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan 430207, China;
      • b. University of Chinese Academy of Sciences, Beijing 100049, China;
      • c. Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang 050017, China;
      • d. Department of Infectious Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China;
      • e. Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China;
      • f. Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei 230026, China
      • Received Date: 13 June 2026
      • Accepted Date: 26 August 2026

      Abstract: Ebola virus (EBOV) causes severe and often fatal Ebola virus disease (EVD) in humans, posing a major threat to global public health. Since EVD was first identified in the Democratic Republic of Congo (DRC) in 1976, the World Health Organization (WHO) has declared it a Public Health Emergency of International Concern (PHEIC) on three occasions. EBOV infection is characterized by rapid progression from non-specific febrile illness to severe gastrointestinal symptoms, followed by hemorrhagic fever and multi-organ dysfunction, with case fatality rates reaching as high as 90%. The liver is a primary target of EBOV, and virus-induced liver injury is characterized by elevated aspartate aminotransferase (AST) levels, mild hyperbilirubinemia, impaired coagulation factor synthesis, hepatocyte necrosis, and robust inflammatory responses, all of which are closely correlated with disease severity and mortality risk. In this review, we summarize the characteristics and mechanisms of EBOV-induced liver injury, which may help to further elucidate the pathogenesis of EVD and provide novel strategies for combating EBOV infection.

        HTML

      Figure (1)  Reference (75) Relative (20)

      目录

      This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return